BRCA2 is a gene on chromosome 13 that helps your cells repair damaged DNA. When this gene carries a harmful mutation, the repair process breaks down, and cells become far more likely to develop into cancer. Women who inherit a BRCA2 mutation face a 69% cumulative risk of breast cancer by age 80 and a 17% risk of ovarian cancer. Men with the mutation also face elevated risks for breast and prostate cancer. About 1 in 400 people in the general population carry a BRCA1 or BRCA2 mutation, though the rate is significantly higher in certain ethnic groups.
How BRCA2 Protects Your DNA
Every cell in your body sustains DNA damage regularly, from normal metabolism, sunlight, or environmental toxins. One of the most dangerous types of damage is a double-strand break, where both rails of the DNA ladder snap. Your cells have a precise repair system called homologous recombination that fixes these breaks using the intact copy of the chromosome as a template.
The BRCA2 protein is essential to this process. When a double-strand break occurs, BRCA2 helps load a repair protein called RAD51 onto the exposed single strand of DNA. RAD51 then searches for matching DNA on the sister chromosome and guides the broken strand back into alignment so it can be accurately rebuilt. Without functional BRCA2, this high-fidelity repair system fails. Cells are forced to rely on sloppier backup methods that introduce errors, and those errors accumulate over time into the kind of mutations that drive cancer.
Cancer Risks for Women
The cancer most strongly associated with BRCA2 mutations is breast cancer. The cumulative risk by age 80 reaches about 69%, compared to roughly 13% for the general female population. Ovarian cancer risk rises to approximately 17%, well above the general population’s lifetime risk of about 1.2%. These risks are high enough that many carriers choose intensive screening or preventive surgery.
BRCA2-related breast cancers tend to develop somewhat later than those linked to BRCA1 mutations, often appearing after age 40 rather than in the 30s. They are also more likely to be hormone receptor-positive, which can affect treatment options.
Cancer Risks for Men
BRCA2 is not just a women’s health concern. Men with a BRCA2 mutation have an estimated 1.8% to 7.1% chance of developing breast cancer by age 70. That may sound modest, but the baseline risk for men is less than 0.1%, making this a meaningful increase.
Prostate cancer is the bigger risk. Studies estimate that 19% to 61% of men with harmful BRCA2 changes will develop prostate cancer by age 80. BRCA2-associated prostate cancers also tend to be more aggressive and diagnosed at a more advanced stage than typical prostate cancers, which makes awareness and early screening particularly valuable for male carriers.
Pancreatic Cancer and Other Risks
BRCA2 mutations raise the lifetime risk of pancreatic cancer to roughly 4.9%. That’s several times higher than the general population risk of about 1.5%. Female carriers over age 50 who also have a first-degree relative with pancreatic cancer face an annual risk of about 1%, which is high enough to warrant discussion with a specialist about surveillance options. BRCA2 mutations have also been linked to increased rates of melanoma and stomach cancer, though the absolute risk increases for these cancers are smaller.
How BRCA2 Mutations Are Inherited
BRCA2 mutations follow an autosomal dominant inheritance pattern, which means you only need one copy of the mutated gene (from one parent) to carry the increased cancer risk. If a parent has a BRCA2 mutation, each child has a 50% chance of inheriting it, regardless of sex. Men pass the mutation to their children just as readily as women do.
It’s worth noting that inheriting one mutated copy doesn’t mean cancer is inevitable. Your cells still have a second, working copy of BRCA2. Cancer typically develops only after that second copy is lost or damaged in a specific cell, a random event that happens more frequently over a lifetime but isn’t guaranteed. This is why cancer risk is high but not 100%.
In rare cases, a child inherits mutated BRCA2 from both parents. This causes a severe condition called Fanconi anemia (subtype D1), a childhood disorder involving bone marrow failure, developmental abnormalities, and very high cancer risk early in life. This subtype accounts for about 3% of all Fanconi anemia cases.
Who Is Most Likely to Carry a Mutation
BRCA2 mutations occur across all ethnicities, but they are especially concentrated in people of Ashkenazi Jewish descent. In this population, about 1 in 40 people carry one of three specific founder mutations in BRCA1 or BRCA2. In the general population, the carrier rate is closer to 1 in 400. Other populations with elevated rates include people of Icelandic, Dutch, and French-Canadian ancestry, each with their own characteristic mutations.
Family history is the strongest clue. Multiple cases of breast cancer (especially before age 50), any male breast cancer, ovarian cancer at any age, or pancreatic cancer in the family all raise the likelihood that a BRCA2 mutation is involved. Genetic testing through a blood or saliva sample can confirm carrier status.
Screening for BRCA2 Carriers
Because standard screening guidelines are designed for average-risk individuals, BRCA2 carriers need a more intensive approach. Research supports starting annual breast MRI at age 25, with mammography added at age 30. For BRCA2 carriers specifically, delaying mammography to 30 (rather than 25) helps reduce cumulative radiation exposure during the years when breast tissue is most sensitive, while MRI, which uses no radiation, provides early coverage.
Screening recommendations for other BRCA2-associated cancers are less standardized. Some specialists recommend prostate cancer screening starting at age 40 for male carriers. Pancreatic cancer surveillance is generally considered only for carriers who also have a family history of the disease, since the absolute risk, while elevated, is still relatively low for most carriers.
How Treatment Targets BRCA2-Deficient Cancers
One of the most significant treatment advances for BRCA2 carriers involves a class of drugs called PARP inhibitors. These drugs exploit a vulnerability unique to cancer cells that have lost both copies of BRCA2.
Here’s the logic: PARP is a protein your cells use for a different, more basic type of DNA repair. In normal cells, if you block PARP, the cell can still fix DNA through the BRCA2-dependent repair system. But in cancer cells where BRCA2 is already broken, blocking PARP removes the last remaining repair pathway. The cancer cell accumulates so much DNA damage that it dies. Normal cells, which still have one working copy of BRCA2, survive the treatment largely unharmed. This concept, called synthetic lethality, is why PARP inhibitors can be highly selective, killing cancer cells while causing relatively limited side effects compared to traditional chemotherapy. PARP inhibitors are now approved for treating BRCA-associated ovarian, breast, pancreatic, and prostate cancers.